Chen Hongming 4
4 · Kala Pharmaceuticals, Inc. · Filed Jan 5, 2021
Insider Transaction Report
Form 4
Chen Hongming
Chief Scientific Officer10% Owner
Transactions
- Award
Common Stock
2021-01-04+22,666→ 186,515 total - Award
Stock Option (right to buy)
2021-01-04+90,667→ 90,667 totalExercise: $6.86Exp: 2031-01-03→ Common Stock (90,667 underlying)
Footnotes (3)
- [F1]Grant of restricted stock units ("RSUs") under the Issuer's 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued employment with Issuer, the RSUs will vest as to 1/3 of the shares underlying the RSUs on January 4, 2022, as to 1/3 of the shares underlying the RSUs on January 4, 2023 and as to the final 1/3 of shares underlying the RSUs on January 4, 2024.
- [F2]Includes 99,666 unvested RSUs.
- [F3]This option was granted on January 4, 2021 and vests with respect to 1/48th of the shares underlying the option at the end of each successive one-month period thereafter.